LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2015.
“We are pleased with the continued progress of our pipeline over the last quarter. In particular, we are encouraged by the progress Avanir has made with AVP-786 in 2015. We see a continued commitment by Avanir to broadly evaluate the potential of AVP-786 in multiple neurological disorders including Alzheimer’s agitation, schizophrenia and depression,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume. .
